Antifungal drug resistance of pathogenic fungi

DP Kontoyiannis, RE Lewis - The Lancet, 2002 - thelancet.com
Pathogenic fungi have many complex mechanisms of resistance to antifungal drugs.
Information about the clinical, cellular, and molecular factors contributing to antifungal-drug …

Invasive aspergillosis in 2002: an update

D Kontoyiannis, G Bodey - European Journal of Clinical Microbiology and …, 2002 - Springer
Despite significant advances in the management of immunosuppressed patients, invasive
aspergillosis remains an important life-threatening complication. In the past two decades …

British Association of Dermatologists' guidelines for the management of onychomycosis 2014

M Ameen, JT Lear, V Madan… - British Journal of …, 2014 - academic.oup.com
The clinical signs of tinea unguium are often difficult to distinguish from those of a number of
other infectious causes of nail damage, such as Candida, mould or bacterial infection. 5 …

Antifungal properties of new series of quinoline derivatives

R Musiol, J Jampilek, V Buchta, L Silva… - Bioorganic & Medicinal …, 2006 - Elsevier
The series of quinoline derivatives were prepared. The synthetic approach, analytical, and
spectroscopic data of all synthesized compounds are presented. All the prepared derivatives …

Management of candidiasis Management of Candida species infections in critically ill patients

P Eggimann, J Garbino, D Pittet - The lancet infectious diseases, 2003 - thelancet.com
Invasive candidiasis is a feared infection with mortality similar to that of septic shock (40–
60%). Improved knowledge of its pathophysiology and the availability of new compounds for …

In Vitro Drug Interaction Modeling of Combinations of Azoles with Terbinafine against Clinical Scedosporium prolificans Isolates

J Meletiadis, JW Mouton, JFGM Meis… - Antimicrobial Agents …, 2003 - Am Soc Microbiol
The in vitro interaction between terbinafine and the azoles voriconazole, miconazole, and
itraconazole against five clinical Scedosporium prolificans isolates after 48 and 72 h of …

Updated perspectives on the diagnosis and management of onychomycosis

JM Falotico, SR Lipner - Clinical, Cosmetic and Investigational …, 2022 - Taylor & Francis
Onychomycosis is the most common nail disease encountered in clinical practice and can
cause pain, difficulty with ambulation, and psycho-social problems. A thorough history and …

Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy

R Baran, A Kaoukhov - Journal of the European Academy of …, 2005 - Wiley Online Library
Background Onychomycosis is a relatively common disease accounting for up to 50% of all
nail disorders and its prevalence rises with age. As onychomycosis is an important medical …

Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to …

WJ Steinbach, DA Stevens… - Clinical Infectious …, 2003 - academic.oup.com
The development of newer antifungal drugs is creating new potential combination therapies
to combat the dismal mortality rate associated with invasive aspergillosis (IA). The efficacy of …

Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society …

M Ruhnke, OA Cornely, M Schmidt‐Hieber, N Alakel… - Mycoses, 2020 - Wiley Online Library
Background Invasive fungal diseases remain a major cause of morbidity and mortality in
cancer patients undergoing intensive cytotoxic therapy. The choice of the most appropriate …